Kynd Revenue and Competitors
Estimated Revenue & Valuation
- Kynd's estimated annual revenue is currently $2.2M per year.
- Kynd's estimated revenue per employee is $101,500
Employee Data
- Kynd has 22 Employees.
- Kynd grew their employee count by -21% last year.
Kynd's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Product Manager | Reveal Email/Phone |
2 | Support Specialist | Reveal Email/Phone |
Kynd Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $60M | 331 | 24% | N/A | N/A |
#2 | $5.3M | 46 | -6% | N/A | N/A |
#3 | $36.8M | 236 | -3% | $46.9M | N/A |
#4 | $15.1M | 104 | 4% | N/A | N/A |
#5 | $1.4M | 16 | -6% | N/A | N/A |
#6 | $1.4M | 16 | -6% | N/A | N/A |
#7 | $3.5M | 30 | -12% | N/A | N/A |
#8 | $146M | 719 | 6% | N/A | N/A |
#9 | $99.7M | 550 | -1% | N/A | N/A |
#10 | $12.9M | 89 | -3% | $3.5M | N/A |
What Is Kynd?
The simple way to find and book #NDIS support.
keywords:N/AN/A
Total Funding
22
Number of Employees
$2.2M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kynd News
A batch of anti-anxiety medication has been recalled by Australia's peak medical regulatory body following reports of unexpected allergic...
A batch of anti-anxiety medication has been recalled by Australia's peak medical regulatory body following reports of unexpected allergic...
The allergic reaction symptoms to watch out for include a rash, tingling or burning skin, skin redness or itching, and swelling of the...
The allergic reaction symptoms to watch out for include a rash, tingling or burning skin, skin redness or itching, and swelling of the...
Sales of Kynd began this week across Liberty's 45-dispensary footprint. The initial launch includes six strain offerings, namely Blueberry...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.1M | 26 | -38% | N/A |
#2 | $3.1M | 27 | 4% | N/A |
#3 | $5.1M | 31 | 3% | N/A |
#4 | $3.9M | 34 | -8% | N/A |
#5 | $5.8M | 36 | -23% | N/A |